18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer.

Saved in:
Bibliographic Details
Title: 18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer.
Authors: Peterson LM; Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington., Kurland BF; Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania., Yan F; Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington., Jiresova AN; Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic., Gadi VK; Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington.; Clinical Research and Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Specht JM; Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington., Gralow JR; Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington., Schubert EK; Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania., Link JM; Department of Diagnostic Radiology, Oregon Health and Science University, Portland, Oregon; and., Krohn KA; Department of Diagnostic Radiology, Oregon Health and Science University, Portland, Oregon; and., Eary JF; Cancer Imaging Program, National Cancer Institute, Bethesda, Maryland., Mankoff DA; Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania., Linden HM; Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington hmlinden@uw.edu.
Source: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2021 Feb; Vol. 62 (2), pp. 184-190. Date of Electronic Publication: 2020 Jun 26.
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1535-5667
DOI:10.2967/jnumed.120.244459